Management of end stage heart failure

Heart

Volumn 93, Issue 5, 2007, Pages 626-631

  Friedrich, Erik B ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENOXIMONE; METOPROLOL; MILRINONE; PHOSPHODIESTERASE INHIBITOR; SPIRONOLACTONE; VASOPRESSIN RECEPTOR ANTAGONIST; CARDIOTONIC AGENT;

AORTA BALLOON; DISEASE CLASSIFICATION; HEART ASSIST DEVICE; HEART FAILURE; HEART SURGERY; HUMAN; PRIORITY JOURNAL; REVIEW; CONGESTIVE HEART FAILURE; EXPERIMENTAL THERAPY; METHODOLOGY; PALLIATIVE THERAPY; THORAX SURGERY;

CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; PALLIATIVE CARE; THERAPIES, INVESTIGATIONAL; THORACIC SURGICAL PROCEDURES;

EID: 34247850846     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.098814     Document Type: Review

References (37)

1. Hoppe UC, Böhm M, Dietz R, et al. Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 2005;94:488- 509. ▶ Current recommendations of the German Cardiac Society for the treatment of chronic heart failure.
2. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115- 40. ▶ Current ESC practice guidelines; compare with reference 1.
3. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-82. ▶ Current ACC/AHA practice guidelines including comprehensive overview of the literature until 2005, together with references 1 and 2.
4. Cleland JG, Gemmell I, Khand A, et al. Is the prognosis of heart failure improving? Eur J Heart Fail 1999;1:229-41.
5. Böhm M, Werner N, Kindermann M. Drug treatment for chronic heart failure. Clin Res Cardiol 2006;95(suppl 4):36-56.
6. Flather M, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial infarction Collaborative Group. Lancet 2000;355:1575-81. ▶ Meta-analysis of clinical trials on the use of ACE inhibitors in heart failure.
7. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.
8. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
9. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
10. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001;134:550- 60. ▶ Meta-analysis of clinical trials on the use of β-blockers in heart failure.
11. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17. ▶ Landmark trial showing that aldosterone antagonism improves mortality in heart failure.
12. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
13. Khand AU, Rankin AC, Kaye GC, et al. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 2000;21:614-32.
14. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
15. Levy S, Breithardt G, Campbell RW, et al. Atrial-fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1998;19:1294-320.
16. Torp-Pedersen C, Moller M, Bloch Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341:857-65.
17. Task Force on AHF. Executive summary of the guidelines on the diagnosis and treatment of AHF: The Task Force on AHF of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
18. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002;360:196-202.
19. Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JEUS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006;8:105-10.
20. Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail 2003;9:188-91.
21. Cohn JN, Archibald DG, Phil M, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperation study. N Engl J Med 1986;314:1547-52.
22. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57.
23. Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronization therapy with or without implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50. ▶ First study to show that CRT improves mortality in heart failure.
24. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
25. Götze S, Butter C, Fleck E. Cardiac resynchronization therapy for heart failure - from experimental pacing to evidence-based therapy. Clin Res Cardiol 2006;95(suppl 4):18-35.
26. Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death. J Am Coll Cardiol 2003;41:1573-82. ▶ Meta-analysis of trials on secondary prevention of SCD.
27. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83. ▶ First study to implicate ICD implantation for primary prevention of SCD in patients with severe LV dysfunction.
28. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
29. Hosenpud JD, Bennett LE, Keck BM, et al. The registry of the International Society for Heart and Lung Transplantation: sixteenth official report-1999. J Heart Lung Transplant 1999;18:611-26.
30. El Banayosy A, Deng M, Loisance DY, et al. The European experience of Novacor left ventricular assist (LVAS) therapy as a bridge to transplant: a retrospective multi centre study. Eur J Cardiothorac Surg 1999;15:835-41.
31. Copeland JG, Smith RG, Arabia FA, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004;351:859-67.
32. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. N Engl J Med 2001;345:1435-43. ▶ Landmark study establishing LVADs as destination therapy in end stage heart failure.
33. Deng MC, Weyand M, Hammel D, et al. Selection and management of ventricular assist device patients: the Muenster experience. J Heart Lung Transplant 2000;19(suppl 8):S77-82.
34. Geha AS, El-Zein C, Massad MG. Mitral valve surgery in patients with ischemic and nonischemic dilated cardiomyopathy. Cardiology 2004;101:15-20.
35. Wollert KC, Drexler H. Cell-based therapy for heart failure. Curr Opin Cardiol 2006;21:234-9.
36. Guccione JM, Salahieh A, Moonly SM, et al. Myosplint decreases wall stress without depressing function of the failing heart: a finite element model study. Ann Thorac Surg 2003;76:1171-80.
37. Oz MC, Konertz WF, Kleber FX, et al. Global surgical experience with the Acorn cardiac support device. J Thorac Cardiovasc Surg 2003;126:983-91.